Literature DB >> 16389009

The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience.

Ali Ayhan1, Murat Gultekin, Cagatay Taskiran, Guldeniz Aksan, Nilufer Yigit Celik, Polat Dursun, M Coskun Salman, Kunter Yuce, Turkan Kucukali.   

Abstract

OBJECTIVE: This study was undertaken to evaluate the role of secondary cytoreduction in patients with recurrent epithelial ovarian cancer. STUDY
DESIGN: Secondarily, cytoreduced patients were retrospectively analyzed with respect to the clinicopathologic variables.
RESULTS: A total of 64 patients were evaluated in this report. Multivariable analysis revealed 3 factors to be significant: optimal cytoreduction during primary (P = .003, odds ratio [OR]: 0.30; 95% CI: 0.14-0.66), secondary cytoreduction (P = .04, OR: 0.47; 95% CI: 0.22-0.99), and the endometrioid histologic type (P = .005, OR: 0.09; 95% CI: 0.02-0.48). Intrinsic factors of the tumors (grade, stage, age), size, and number of recurrent tumors were nonsignificant.
CONCLUSION: Secondary cytoreductive surgery should be offered in selected recurrent epithelial ovarian cancer patients. Further prospective randomized series are needed to determine specific recommendations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16389009     DOI: 10.1016/j.ajog.2005.06.048

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

Review 1.  Ovarian cancer: the duplicity of CA125 measurement.

Authors:  Amer K Karam; Beth Y Karlan
Journal:  Nat Rev Clin Oncol       Date:  2010-04-06       Impact factor: 66.675

2.  Maximal cytoreductive effort in epithelial ovarian cancer surgery.

Authors:  Karin K Shih; Dennis S Chi
Journal:  J Gynecol Oncol       Date:  2010-06-30       Impact factor: 4.401

3.  Survival Impact of Secondary Cytoreductive Surgery for Recurrent Ovarian Cancer in an Asian Population.

Authors:  Rani Akhil Bhat; Yin Nin Chia; Yong Kuei Lim; Kwai Lam Yam; Cindy Lim; Melissa Teo
Journal:  Oman Med J       Date:  2015-09

4.  Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer.

Authors:  Jaeman Bae; Myong Cheol Lim; Jae-Ho Choi; Yong-Joong Song; Kyoung-Soo Lee; Sokbom Kang; Sang-Soo Seo; Sang-Yoon Park
Journal:  J Gynecol Oncol       Date:  2009-06-29       Impact factor: 4.401

Review 5.  Surgical cytoreduction for recurrent epithelial ovarian cancer.

Authors:  Thuria Al Rawahi; Alberto D Lopes; Robert E Bristow; Andrew Bryant; Ahmed Elattar; Supratik Chattopadhyay; Khadra Galaal
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

6.  The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis.

Authors:  Ting Ding; Dan Tang; Mingrong Xi
Journal:  J Ovarian Res       Date:  2021-07-13       Impact factor: 4.234

7.  The role of secondary surgery in recurrent ovarian cancer.

Authors:  D Lorusso; M Mancini; R Di Rocco; R Fontanelli; F Raspagliesi
Journal:  Int J Surg Oncol       Date:  2012-08-05

8.  Safety and efficacy of video laparoscopic surgical debulking of recurrent ovarian, fallopian tube, and primary peritoneal cancers.

Authors:  Farr R Nezhat; Shaghayegh M Denoble; Jennifer E Cho; Douglas N Brown; Enrique Soto; Linus Chuang; Herbert Gretz; Prakash Saharia
Journal:  JSLS       Date:  2012 Oct-Dec       Impact factor: 2.172

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.